Vanguard Group Inc. grew its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 5.8% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 44,087,287 shares of the company's stock after buying an additional 2,404,232 shares during the period. Vanguard Group Inc. owned 6.06% of Roivant Sciences worth $521,553,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also made changes to their positions in the company. Charles Schwab Investment Management Inc. boosted its holdings in Roivant Sciences by 30.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 2,767,412 shares of the company's stock valued at $31,936,000 after acquiring an additional 646,627 shares during the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of Roivant Sciences by 10.8% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 356,600 shares of the company's stock worth $4,115,000 after purchasing an additional 34,641 shares during the period. MetLife Investment Management LLC lifted its stake in shares of Roivant Sciences by 26.3% in the 3rd quarter. MetLife Investment Management LLC now owns 225,320 shares of the company's stock valued at $2,600,000 after purchasing an additional 46,879 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Roivant Sciences by 49.4% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,307,178 shares of the company's stock worth $26,625,000 after purchasing an additional 762,953 shares during the period. Finally, Edgestream Partners L.P. acquired a new stake in Roivant Sciences during the 3rd quarter worth approximately $557,000. 64.76% of the stock is currently owned by institutional investors and hedge funds.
Roivant Sciences Stock Performance
Shares of ROIV stock traded down $0.55 during trading hours on Friday, reaching $9.46. The company had a trading volume of 10,135,922 shares, compared to its average volume of 5,313,953. The company has a market capitalization of $6.75 billion, a P/E ratio of -63.06 and a beta of 1.25. Roivant Sciences Ltd. has a twelve month low of $9.42 and a twelve month high of $13.06. The stock's fifty day simple moving average is $10.62 and its 200 day simple moving average is $11.33.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last issued its quarterly earnings data on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. As a group, equities analysts expect that Roivant Sciences Ltd. will post -0.92 earnings per share for the current year.
Analysts Set New Price Targets
A number of brokerages have weighed in on ROIV. HC Wainwright reaffirmed a "buy" rating and set a $18.00 price target on shares of Roivant Sciences in a research report on Tuesday, February 11th. Cantor Fitzgerald raised shares of Roivant Sciences to a "strong-buy" rating in a research note on Tuesday, March 4th.
View Our Latest Analysis on ROIV
Insider Activity
In other Roivant Sciences news, CAO Rakhi Kumar sold 227,500 shares of Roivant Sciences stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the sale, the chief accounting officer now directly owns 163,264 shares in the company, valued at $1,702,843.52. The trade was a 58.22 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Eric Venker sold 218,041 shares of the company's stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $10.42, for a total value of $2,271,987.22. Following the completion of the transaction, the chief operating officer now directly owns 896,869 shares in the company, valued at approximately $9,345,374.98. The trade was a 19.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,395,541 shares of company stock worth $15,028,538. 7.90% of the stock is currently owned by company insiders.
Roivant Sciences Profile
(
Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Read More
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
